Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Eli Lilly and Company (MARCS-CMS 716475)

FDA has issued 3 warning letters to Eli Lilly and Company:

Letter facts

Letter date
September 9, 2025 (2025-09-09)
Issuing office
Center for Drug Evaluation and Research (CDER)
Products named
ZEPBOUND® (tirzepatide) injection, for subcutaneous use
Violation categories
MisbrandingFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says a promotional video for Zepbound omitted all risk information and limitations of use, creating a misleading impression of the drug's safety and approved use, and that the video was not submitted to FDA on Form FDA-2253 at initial publication.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • False or misleading risk presentation
  • Omission of material facts
  • Failure to submit under Form FDA-2253

More letters about Tirzepatide

Recent FDA warning letters concerning Tirzepatide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.